Pharmaceuticals Global On demand · 24-48h

Global Anti-androgen Drugs Market Strategic Research Report

Global Anti-androgen Drugs Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Anti-androgen Drugs Market
$7.43B2025
13%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: NSARIs, SARIs, ASIs

By Application: nmCRPC, mCRPC, mHSPC, Special Endocrine / Female

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Astellas, Pfizer, Johnson & Johnson, Bayer AG, Orion, Teva Pharmaceutical, Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, Hengrui Pharmaceuticals, Lonza Group, WuXi AppTec, Asymchem Laboratories, Catalent

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 121 pages
Market size 2025
$7.43B
Billion USD
Forecast CAGR
13%
2025-2032
Forecast 2032
$17.5B
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Anti-androgen Drugs market size is predicted to grow from US$ 7,432 million in 2025 to US$ 17,786 million in 2032; it is expected to grow at a CAGR of 13.0% from 2026 to 2032.

Anti-androgen drugs are a class of therapeutics that inhibit androgen production, block androgen receptor (AR) signaling, or interfere with downstream androgen pathways, primarily used to treat androgen-dependent diseases, with prostate cancer as the core indication, while also covering conditions such as polycystic ovary syndrome (PCOS), hirsutism, and gender-affirming hormone therapy; the category includes non-steroidal AR inhibitors (e.g., Enzalutamide, Apalutamide, Darolutamide), steroidal anti-androgens (e.g., Cyproterone Acetate), and androgen biosynthesis inhibitors (e.g., Abiraterone Acetate), forming a comprehensive market characterized by mechanistic diversity and indication-driven demand.

Global key Anti-androgen Drugs players cover Astellas, Pfizer, Johnson & Johnson, Bayer AG, Orion, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-androgen Drugs market?

What factors are driving Anti-androgen Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-androgen Drugs market opportunities vary by end market size?

How does Anti-androgen Drugs break out by Type, by Application?

This report presents a comprehensive overview of the global Anti-androgen Drugs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • NSARIs
  • SARIs
  • ASIs

Segment by Generation

  • 1st Gen
  • 2nd Gen

Segment by Application

  • nmCRPC
  • mCRPC
  • mHSPC
  • Special Endocrine / Female

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Anti-androgen Drugs market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in nmCRPC, mCRPC, mHSPC evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Anti-androgen Drugs Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 13%
Regional growth momentum
Market share by segment
Key metrics
Base value
$7.43B
2025
Forecast
$17.5B
2032
CAGR
13%
2025–2032
Regiones
5
global
Key companies
AstellasPfizerJohnson & JohnsonBayer AGOrionTeva PharmaceuticalSun PharmaceuticalDr. Reddy's Laboratories
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
NSARIsSARIsASIs
By Application
nmCRPCmCRPCmHSPCSpecial Endocrine / Female

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 NSARIs
  • 3.1.3 SARIs
  • 3.1.4 ASIs
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 nmCRPC
  • 4.1.3 mCRPC
  • 4.1.4 mHSPC
  • 4.1.5 Special Endocrine / Female
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Astellas
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Pfizer
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Johnson & Johnson
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Bayer AG
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Orion
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Teva Pharmaceutical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Sun Pharmaceutical
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Dr. Reddy's Laboratories
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Cipla
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Hengrui Pharmaceuticals
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Lonza Group
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 WuXi AppTec
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Asymchem Laboratories
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Catalent
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Anti-androgen Drugs market?
The global Anti-androgen Drugs market is estimated at US$ 7.43 billion in 2025 (base year) and is projected to reach US$ 17.79 billion by 2032.
What is the forecast CAGR for the Anti-androgen Drugs market?
The market is expected to grow at a CAGR of 13.0% from 2026 to 2032, expanding from US$ 7.43 billion in 2025 to US$ 17.79 billion in 2032, roughly 2.4 times its base-year value.
What is Anti-androgen Drugs?
Anti-androgen drugs are a class of therapeutics that inhibit androgen production, block androgen receptor (AR) signaling, or interfere with downstream androgen pathways, primarily used to treat androgen-dependent diseases, with prostate cancer as the core indication, while also covering conditions such as polycystic ovary syndrome (PCOS), hirsutism, and gender-affirming hormone therapy; the category includes non-steroidal AR inhibitors (e.g., Enzalutamide, Apalutamide, Darolutamide), steroidal anti-androgens (e.g., Cyproterone Acetate), and androgen biosynthesis inhibitors (e.g., Abiraterone Acetate), forming a comprehensive market characterized by mechanistic diversity and.
How is the Anti-androgen Drugs market segmented by type?
By type, the market is segmented into NSARIs, SARIs and ASIs.
What are the key applications of Anti-androgen Drugs?
Key applications covered include nmCRPC, mCRPC, mHSPC and Special Endocrine / Female.
Which companies are profiled in the Anti-androgen Drugs market report?
Key players profiled include Astellas, Pfizer, Johnson & Johnson, Bayer AG, Orion, Teva Pharmaceutical, Sun Pharmaceutical and Dr. Reddy's Laboratories, among 14 companies covered in total.
What geographies does the Anti-androgen Drugs market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Anti-androgen Drugs?
What factors are driving Anti-androgen Drugs market growth, globally and by region?
Who should buy the Anti-androgen Drugs market report?
The report is intended for manufacturers and solution providers, distributors and end users in nmCRPC, mCRPC and mHSPC, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Anti-androgen Drugs market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.